20/20 Biolabs (NASDAQ:AIDX) Posts Quarterly Earnings Results

20/20 Biolabs (NASDAQ:AIDX) announced its quarterly earnings results on Wednesday. The company reported ($0.28) EPS for the quarter, FiscalAI reports. The company had revenue of $0.35 million during the quarter.

20/20 Biolabs Stock Down 3.7%

Shares of 20/20 Biolabs stock opened at $1.29 on Thursday. 20/20 Biolabs has a 12 month low of $1.26 and a 12 month high of $50.00. The firm’s fifty day moving average price is $1.77.

Wall Street Analyst Weigh In

A number of analysts recently commented on AIDX shares. Weiss Ratings started coverage on 20/20 Biolabs in a research note on Thursday, May 14th. They issued a “sell (e-)” rating for the company. Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. Finally, Maxim Group started coverage on 20/20 Biolabs in a research note on Monday, May 11th. They issued a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.